In yet an­oth­er de­lay for the F-star buy­out, CFIUS ex­tends re­view of 'na­tion­al se­cu­ri­ty risks'

F-star Ther­a­peu­tics $FSTX has been forced to ex­tend its long streak of de­lays for the pro­posed takeover deal by Chi­na’s Sino Bio­pharm, rais­ing the risk the buy­out may not get a green light as a US com­mit­tee tasked with re­view­ing for­eign in­vest­ments rais­es “na­tion­al se­cu­ri­ty con­cerns.”

On Mon­day the biotech filed no­tice of the Com­mit­tee on For­eign In­vest­ment in the Unit­ed States’ de­ci­sion that it is ex­tend­ing its re­view by 45 days, which puts it on track to make a de­ci­sion by the end of Jan­u­ary — un­less they de­cide to de­lay it again. The biotechs then ex­tend­ed their buy­out pact to the end of De­cem­ber, the lat­est in a long string of de­lays since they an­nounced the deal last June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER